<![CDATA[NDA Submission Begins for Zipalertinib Combo in First-Line EGFR+ NSCLC]]>

NDA FilingzipalertinibPositive

AI Analysis

Summary

Trax Pharmaceuticals has submitted an NDA for zipalertinib in combination with chemotherapy for first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations, supported by positive REZILIENT3 trial data.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

NDA submission initiated for zipalertinib plus chemotherapy combination in first-line EGFR+ NSCLC

Importance:7/10

Sentiment:

0.60

NDA filingNSCLCEGFR mutationREZILIENT3 trialcombination therapy

Related Companies

$TRAX

Read the original article

Published by Cancer Network on October 5, 2026 5:00 PM

Read Original